ProKidney Q2 FY26 net loss widens to $46.44 million; revenue falls to $150,000

• ProKidney posted Q2 2026 revenue of $150,000, down 32.13% from a year earlier.
• Net loss before noncontrolling interest widened to $46.4 million from $37 million a year earlier.
• R&D expense climbed 39.39% to $36.1 million, driven by higher clinical study and related manufacturing costs tied to PROACT 1.
• Cash, cash equivalents and marketable securities fell to $181.6 million at June 30 from $224.9 million at March 31, supporting operations into mid-2027.
• Completed enrollment for the PROACT 1 accelerated approval analysis, with pivotal eGFR slope topline results anticipated in Q2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prokidney Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608101605PRIMZONEFULLFEED9807021) on August 10, 2026, and is solely responsible for the information contained therein.